Guidelines on the clinical use of leucocyte‐depleted blood components
Authors: Napier  , Chapman  , Forman  , Kelsey  , Knowles  , Murphy  , Williamson  , Wood  , Kinsey  , Murphy  , Pamphilon  , Warwick  
Published: March 2003

Definition:Leucocyte‐depleted blood components must contain < 5 × 106 leucocytes per unit (red cells) or adult therapeutic dose (platelets).Practical aspects:To achieve residual leucocyte counts of < 5 × 106, leucocyte‐depletion should be carried out under controlled conditions, ideally within 48 h from the collection of the donor unit. The preparation of leucocyte‐depleted blood components should be subject to a quality monitoring programme designed to assure 100% compliance. Indications for leucocyte‐depleted blood components RECOMMENDEDFebrile nonhaemolytic transfusion reactions (FNHTRs) 1 To prevent recurrent FNHTRs after red‐cell transfusions, buffy coat‐depleted red‐cell concentrates should be used, if they are available, or alternatively red‐cell concentrates filtered at the bedside. 2 If FNHTRs continue despite these measures, leucocyte‐depleted red‐cell concentrates should be used. 3 To prevent FNHTRs in patients likely to be dependent on long‐term red‐cell support, the use of buffy‐coat‐depleted or bedside filtered red‐cell concentrates should be considered from the outset of transfusion support. 4 The routine use of pooled platelets derived from buffy coats is associated with a low incidence of FNHTRs. The use of platelet concentrates leucocyte‐depleted prior to storage is recommended for patients with reactions despite the use of such components. Bedside filtration of platelet concentrates is not recommended for the prevention of FNHTRs associated with platelet transfusions.Reducing graft rejection after haemopoietic cell transplantation:Patients with severe aplastic anaemia who are potential haemopoietic cell transplant recipients should receive leucocyte‐depleted blood components from the beginning of transfusion support. The same might apply to patients with haemoglobinopathies, but more evidence is required before a definite recommendation can be made.Prevention of transmission of viral infections by blood transfusion:Leucocyte‐depletion of blood components is an effective alternative to the use of CMV‐seronegative blood components for the prevention of transfusion‐transmitted CMV infection to at‐risk patients.Fetal/neonatal transfusions:Leucocyte‐depleted blood components should be used for intrauterine transfusions and for all transfusions to infants below 1 year of age. POSSIBLEPlatelet refractoriness:There is currently no convincing evidence that routine leucocyte‐depletion of blood components produces clinical benefits for patients receiving multiple platelet transfusions, although HLA alloimmunization and platelet refractoriness are reduced.Kidney transplants:Pretransplant blood transfusion may confer some benefit to renal transplant recipients, although some patients will become alloimmunized leading to difficulties in the selection of donor kidneys. Consideration should be given to the leucocyte‐depletion of transfusions to renal transplant patients to prevent HLA alloimmunization unless they are part of a deliberate pretransplant immunosuppression protocol.Immunomodulation:There is insufficient evidence to recommend the routine use of leucocyte‐depleted blood components for surgical patients for the prevention of either post‐operative infection or tumour recurrence.Progression of HIV infection:There is insufficient evidence to recommend the use of leucocyte‐depleted blood components for reducing the progression of HIV infection. NONINDICATIONS. A significant number of recipients of blood components receive a limited number of transfusions over a short period of time, e.g. most general medical and surgical patients. Leucocyte‐depletion of blood components is not indicated for these recipients unless there is an additional acceptable indication discussed in one of the other sections in this guideline. Prevention of TA‐GvHD is not an indication for leucocyte‐depleted blood components. Gammairradiation of blood components is the standard method for avoiding TA‐GvHD. There is no need to leucocyte‐deplete noncellular blood components such as fresh frozen plasma, cryoprecipitate and blood products prepared from pooled plasma.